SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is capturing significant attention as the community rallies around its organic growth and aggressive 'Sith-themed' branding, with supporters actively pushing for higher market capitalization milestones and celebrating the avoidance of a rug-pull structure. Traders are focused on the stock's strong community-driven momentum and volume spikes, viewing current price action as a consolidation period before the next major leg up.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is facing intense shareholder scrutiny and frustration following a surprise acquisition agreement with Garda Therapeutics, with investors questioning the deal's valuation and potential conflicts of interest. The community is actively discussing the possibility of blocking the tender offer, coordinating with major shareholders, and investigating the timeline of the board's decision-making process.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is currently facing intense community debate as retail investors clash over its volatile price action, with many warning of a potential bubble due to the company's lack of consistent profitability and looming dilution risks. While some traders are riding the aggressive momentum tied to the semiconductor materials sector, others are aggressively shorting the stock, citing heavy insider selling and unsustainable valuation gaps as signs of an inevitable correction.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is facing a tug-of-war between institutional optimism and lingering geopolitical anxiety, as traders monitor massive ETF inflows against potential supply-chain disruptions in the Strait of Hormuz. The community remains deeply divided, with bulls pointing to technical breakouts and supply squeezes while bears warn that unresolved regional conflicts could trigger renewed volatility.

Energous Corp. engages in the development of wireless charging technology. It focuses on the product, WattUp, a wireless power technology consisting of proprietary semiconductor chipsets, software controls, hardware designs, and antennas, that enables radio frequency based charging for electronic devices. The company was founded by Michael Aaron Leabman in 2012 and is headquartered in San Jose, CA.

Energous Corp

Energous Corp is seeing heightened investor attention following a series of positive catalysts, including record annual revenue growth and the strategic expansion of its Ambient IoT platform into European markets. While the community is actively debating the company's long-term commercial scalability and the potential for a short squeeze given its low-float status, some investors are highlighting recent insider activity and institutional accumulation as signs of a structural turnaround.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a significant leadership overhaul that replaced CEO Peter Greenleaf with Chairman Kevin Tang, a move widely interpreted by the community as a strategic signal that the company is being positioned for a potential buyout. Investors are actively debating the implications of this transition, including the acquisition of Kezar Life Sciences and the potential for Tang to leverage the companys remaining assets, such as Lupkynis and the Aritinercept pipeline, to maximize shareholder value.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is currently capturing significant attention as investors react to a major financing update where the company secured a substantial investment from Middle Eastern sovereign wealth funds, de-risking its merger with Warner Bros. Discovery. While the stock experiences volatile price action, the community is actively debating the implications of upcoming shareholder votes, potential short squeezes due to heavy short interest, and the long-term value proposition of new warrant distributions for existing shareholders.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

ProShares UltraPro QQQ is currently a focal point for investors navigating significant market volatility driven by escalating geopolitical tensions in the Middle East and concerns over oil supply disruptions. The community is actively debating the impact of these macro events on growth stocks, with many traders utilizing the ETF for aggressive short-term scalping, hedging, or capturing leveraged moves amid shifting sentiment regarding ceasefire negotiations.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing intense market volatility and price sensitivity as investors react to the stalled U.S.-Iran negotiations regarding the Strait of Hormuz. While some community members view the current price action as a bear trap amidst institutional accumulation, others are bracing for deeper pullbacks, with sentiment heavily influenced by the interplay between ongoing geopolitical tensions and broader macroeconomic signals.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is currently seeing increased market interest following the commissioning of its phase 1a commercial magnet production line in Stillwater, Oklahoma, which positions the company to begin fulfilling orders. The community is actively debating the company's long-term production potential and geopolitical significance against ongoing short-selling pressure and concerns regarding sector-wide regulatory hurdles.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scalable Biotech Manufacturing Unlocks a $14B Market

Scalable Biotech Manufacturing Unlocks a $14B Market Scalable Biotech Manufacturing Unlocks a $14B Market PR Newswire VANCOUVER, BC, March 27, 2026 Issued on behalf of Ava Bio, Inc.VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary The global cell therapy manufacturing...

<ul class="summary-bullets"><li>Moleculin said on Wednesday that it believes it is on track to treat the 45th subject in the first quarter of 2026, and an unblinding of data is expected thereafter.</li><li>To date, 35 subjects have been treated and another 11 are in screening or identified.</li><li>In the first 30 patients treated with Annamycin in the trial, the company reported a preliminary composite complete remission (CRc) rate of 40%.</li></ul>Shares of Moleculin Biotech, Inc., (MBRX) rose 14% on Wednesday after the company said that it is on track to treat the 45th patient with Annamycin as part of its Miracle study.The company is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://moleculin.com/moleculin-miracle-trial-delivers-40-preliminary-blinded-crc-rate-n30/">studying</a> Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy.To date, 35 subjects have been treated and another 11 are in screening or identified. Site investigators are continuing to identify additional subjects and once 45 subjects are treated, the company will make its first data reveal, it said.Moleculin said on Wednesday that it believes it is on track to treat the 45th subject in the first quarter of 2026, and an unblinding of data is expected thereafter.<h2 class="st-heading-2">What Does The Data Show So Far?</h2>In the first 30 patients treated with Annamycin in the trial, the company reported a preliminary composite complete remission (CRc) rate of 40%. Composite remission (CRc) is commonly used to measure early efficacy and safety of novel agents in clinical trials.“The blinded efficacy rates we’re seeing in MIRACLE are exceptionally encouraging,” said Moleculin CEO Walter Klemp. “And, of course, this includes the control arm of cytarabine plus placebo, which suggests that the Annamycin results should be better.”Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRX stock stayed within ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user expressed optimism for the data unblinding. “If good, it will truly be explosive,” they wrote.<stembedurl>https://www.stocktwits.com/stockadrenaline/message/645235658</stembedurl>Another user expects good days ahead.<stembedurl>https://www.stocktwits.com/Dadschuh14/message/645228970</stembedurl><a href="https://stocktwits.com/symbol/MBRX">MBRX shares</a> have lost about 89% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-gains-on-fresh-approval-for-bladder-cancer-drug-in-eu/cZR0UjXR4vV">IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did MBRX Stock Climb 14% Today?

Moleculin Biotech said on Wednesday that it is on track to treat the 45th patient with Annamycin as part of its Miracle study.

Equity

<ul class="summary-bullets"><li>The reverse split will consolidate every 25 shares of outstanding common stock into a single share, while maintaining the current par value of $0.001 per share.</li><li>The split will reduce the number of outstanding shares from roughly 51.7 million to about 2.1 million</li><li>Total authorized share count will remain unchanged at 500 million.</li></ul>&nbsp;Shares of Moleculin Biotech Inc. (MBRX) plunged over 25% on Wednesday to their lowest in five months, after the company announced a reverse stock split.Moleculin Biotech will implement a 1-for-25 reverse stock split of its common stock, effective Dec. 1, 2025, following which, the company’s shares will begin trading on a post-split basis on the Nasdaq Capital Market under the existing ticker symbol MBRX.<h2 class="st-heading-2">The Reverse Split</h2>The reverse split will consolidate every 25 shares of outstanding common stock into a single share, while maintaining the current par value of $0.001 per share. Moleculin added that it will not issue fractional shares, and any shareholder entitled to one will receive a cash payment to replace the fractional amount.The move will significantly reduce the number of outstanding shares from roughly 51.7 million to about 2.1 million, while the total authorized share count will remain unchanged at 500 million.Companies often use reverse splits to avoid being delisted, as primary exchanges require stocks to maintain a minimum price of $1.00. If a stock trades below this level for 30 straight sessions, the company receives a deficiency notice and is given a limited window to lift the share price. A reverse stock split can help the firm regain compliance and keep its listing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/MBRX">MBRX</a> on Stocktwits remained in the ‘bearish’ territory over the past 24 hours.&nbsp;&nbsp;One user believes a share repurchase could go some way in boosting confidence.<stembedurl>https://stocktwits.com/Healthpro/message/637501819</stembedurl>MBRX stock has fallen more than 80% so far this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-de-stock-falling-today/cL538QhREWX">Why Is DE Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Why Did MBRX Stock Plummet Over 25% Today?

Moleculin Biotech will implement a 1-for-25 reverse stock split of its common stock, effective December 1.

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know

Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved its Clinical Trial Application for a pivotal Phase 2B/3 study of Annamycin in combination with cytarabine for patients with relapsed or refractory acute myeloid leukemia.The European Medicines Agency approved the randomized, placebo-controlled trial in all nine European Union countries where Moleculin Biotech filed it.&nbsp;It will include research locations in the U.S. and the Middle East.&nbsp;Moleculin Biotech shares closed 2.86% higher at $1.08 on Monday, before slipping 3.7% to $1.04 in after-hours trading.Researchers will combine the Phase 2B study with Phase 3 testing to measure primary efficacy according to international regulatory requirements.Part A of the trial will recruit between 75 and 90 patients randomly assigned to receive HiDAC with a placebo or one of two FDA-approved Annamycin doses of 190 mg/m² or 230 mg/m².&nbsp;The initial patient data set from 45 participants will become available during the second semester of 2025, and researchers anticipate the second unblinding to occur at the beginning of 2026.&nbsp;The trial will expand to include approximately 220 patients during Phase 3 enrollment (Part B).EMA approval depends on Moleculin providing nonclinical GLP data before starting Part B, necessitating protocol modifications afterward.&nbsp;The trial uses an adaptive design that supports the FDA’s Project Optimus goal of improved oncology dose selection.The company remains on course to deliver its expected interim readout this year, as patient dosing has already started.On Stocktwits, retail sentiment was ‘bullish’ amid a 3,700% surge in 24-hour message volume.Some traders expressed appreciation for the stock’s steady performance, with one noting that market makers were doing a good job “keeping it tight” for those accumulating shares of Moleculin.<stembedurl>https://stocktwits.com/CrisMars/message/614378232</stembedurl>Another described the 2.86% rise of the stock as “decent” and said “low and slow will win the race.”<stembedurl>https://stocktwits.com/BiggPapa/message/614389064</stembedurl>The stock has declined nearly 39% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup 

The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

These five biotech stocks, all belonging to nano-, small- or mid-cap categories, notched the highest jump in Stocktwits message volume in the week ended Feb. 14, 2025:GlycoMimetics Inc. (+550% jump in chatter)GlycoMimetics, a late-stage biotech firm developing glycobiology-based cancer therapies, saw a surge in retail interest after a minor amendment to its merger agreement with Crescent Biopharma. The update refined the financing structure but kept intact the exchange ratio and ownership split. Once the deal closes, Crescent security holders, including new investors, will own about 96.9% of the combined company. Shares are up roughly 16% year-to-date (YTD).GRAIL Inc. (+500% jump in chatter)Cancer detection firm GRAIL made waves after announcing a partnership with Quest Diagnostics (DGX) to distribute its Galleri multi-cancer early detection test. Analysts at Guggenheim viewed the move as a major step toward broader accessibility. The stock has soared over 208% YTD.ADMA Biologics Inc. (+400% jump in chatter)ADMA Biologics, a biopharma company focused on plasma-derived therapies, saw rising buzz ahead of its upcoming fourth-quarter (Q4) earnings. Last month, it issued a preliminary report projecting full-year 2024 revenue between $417 million and $425 million, with total cash holdings exceeding $100 million. Despite the strong forecast, shares remain down more than 8% YTD.Moleculin Biotech Inc. (+295% jump in chatter)Moleculin Biotech gained traction after the FDA provided guidance on its Phase 3 trial for Annamycin, a next-generation anthracycline designed to treat relapsed/refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases. With an adjusted trial size, the company expects its first unblinding in late 2025 and another in early 2026. Shares have climbed over 25% YTD.Exelixis Inc. (+200% jump in chatter)Exelixis, an oncology-focused biotech, saw a surge in discussions after reporting Q4 earnings that topped estimates, prompting analysts to raise their price targets. Citi highlighted continued strength in its Cabometyx franchise and pointed to Zanza as a potential blockbuster drug. Shares are up 4.35% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

This account has been verified as an official MBRX representative.

Verified Account

Moleculin Biotech

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

MBRX
Moleculin Biotech Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest MBRX News

MBRXMoleculin Biotech Inc